Within the next month, at least one late-stage pharmaceutical company from the recent clinical-trial-wins topic will announce either a regulatory filing (NDA/BLA), a licensing partnership above $500M in total deal value, or an acquisition offer above $1B.
Posted 2026-09-09 — 30 days before the deadline, stated before the outcome.
The claim
Within the next month, at least one late-stage pharmaceutical company from the recent clinical-trial-wins topic will announce either a regulatory filing (NDA/BLA), a licensing partnership above $500M in total deal value, or an acquisition offer above $1B.
Reasoning trace
- positive Phase 3 readouts across oncology/COPD/PTSD/Huntington's create licensing pressure
- big pharma routinely responds to strong readouts within 30-60 days
- public deal announcement or FDA filing follows
Evidence so far
8 confirming · 0 denying signals · 4 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 17 times since mint (last on 2026-09-30) — 22% at mint → 79% today.
What to watch
- leading indicator A company from the clinical-trial-wins topic issues a press release or public statement confirming the completion of data analysis and preparation of the NDA/BLA regulatory package.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.